• Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions. Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network. Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.
Antwerp, Belgium / Warsaw, Poland – December 4, 2024 – QbD Group and SciencePharma have reached an agreement for QbD Group to acquire SciencePharma. The deal is expected to close by early 2025, pending antitrust clearance.
Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. ● New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.
Ghent, October 23, 2024 — 4Tissue, a pioneering biotech company revolutionizing regenerative medicine with its cutting-edge, bioresorbable hydrogel tissue mimic has successfully completed a €2M seed funding round including equity investment and non-dilutive grants. Led by three prominent female investors from the life science and business sectors, this funding will enable 4Tissue to accelerate the clinical development of its innovative platform. This investment underscores the transformative potential of 4Tissue in women’s health.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.
  • Fields of application

  • Focus on

  • Content type

  • Showcase

  • Regional News

Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions. Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network. Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.
Antwerp, Belgium / Warsaw, Poland – December 4, 2024 – QbD Group and SciencePharma have reached an agreement for QbD Group to acquire SciencePharma. The deal is expected to close by early 2025, pending antitrust clearance.
Investment led by Boehringer Ingelheim Venture Fund, with the participation of new and existing investors, including Apollo Health Ventures, NRW.Venture, and HTGF. ● New financing will accelerate preclinical development of Refoxy’s lead program in IPF as well as the expansion of its platform to additional age-related indications.
Ghent, October 23, 2024 — 4Tissue, a pioneering biotech company revolutionizing regenerative medicine with its cutting-edge, bioresorbable hydrogel tissue mimic has successfully completed a €2M seed funding round including equity investment and non-dilutive grants. Led by three prominent female investors from the life science and business sectors, this funding will enable 4Tissue to accelerate the clinical development of its innovative platform. This investment underscores the transformative potential of 4Tissue in women’s health.
Anacura, a Ghent-based company offering medical and pharmaceutical analytical services, announces the acquisition of OHMX.bio, a Ghent University spin-off specialized in advanced -omics technology. The acquisition expands the existing anacura group activities at AnaBioTec and Labo Nuytinck towards drug discovery and diagnostics research.